In yesterday's report on Nastech's restructuring, we cited a story that included a reference to the biotech's 197 staffers, which was the payroll number at the beginning of the year. A spokesperson adds that the company had since expanded to 230 workers. Of those, up to 75 will be laid off as the company restructures in the wake of P&G's decision to terminate a $577 million development pact for Nastech's osteoporosis therapy. Report